8 of glucose-stimulated insulin release by angiotensin II in isolated pancreatic islets,” Diabetologia, vol. 47, no. 2, pp. 240– 248, 2004. [18] A. Bo¨kenkamp, M. Domanetzki, R. Zinck, G. Schumann, D. Byrd, and J. Brodehl, “Cystatin C—a new marker of glomerular ﬁltration rate in children independent of age and height,” Pediatrics, vol. 101, no. 5, pp. 875–881, 1998. [19] D. J. Newman, H. Thakkar, R. G. Edwards et al., “Serum cystatin C measured by automated immunoassay: a more sensitive marker of changes in GFR than serum creatinine,” Kidney International, vol. 47, no. 1, pp. 312–318, 1995. [20] M. G. Shlipak, M. J. Sarnak, R. Katz et al., “Cystatin C and the risk of death and cardiovascular events among elderly persons,” The New England Journal of Medicine, vol. 352, no. 20, pp. 2049–2060, 2005. [21] M. G. Shlipak, M. J. Sarnak, R. Katz et al., “Cystatin-C and mortality in elderly persons with heart failure,” Journal of the American College of Cardiology, vol. 45, no. 2, pp. 268–271, 2005. [22] L. A. Stevens, J. Coresh, C. H. Schmid et al., “Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD,” American Journal of Kidney Diseases, vol. 51, no. 3, pp. 395– 406, 2008. [23] D. E. Bild, D. A. Bluemke, G. L. Burke et al., “Multi-ethnic study of atherosclerosis: objectives and design,” American Journal of Epidemiology, vol. 156, no. 9, pp. 871–881, 2002. [24] A. V. Chobanian, G. L. Bakris, H. R. Black et al., “Seventh report of the Joint National Committee on Prevention, Detec- tion, Evaluation, and Treatment of High Blood Pressure,” Hypertension, vol. 42, no. 6, pp. 1206–1252, 2003. [25] W. T. Friedewald, R. I. Levy, and D. S. Fredrickson, “Estima- tion of the concentration of low-density lipoprotein choles- terol in plasma, without use of the preparative ultracen- trifuge,” Clinical Chemistry, vol. 18, no. 6, pp. 499–502, 1972. [26] E. J. Erlandsen, E. Randers, and J. H. Kristensen, “Evaluation of the dade behring N latex cystatin C assay on the dade behring nephelometer II system,” Scandinavian Journal of Clinical and Laboratory Investigation, vol. 59, no. 1, pp. 1–8, 1999. [27] S. M. Grundy, J. I. Cleeman, S. R. Daniels et al., “Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientiﬁc statement,” Circulation, vol. 112, no. 17, pp. 2735– 2752, 2005. [28] R. Li and L. Chambless, “Test for additive interaction in proportional hazards models,” Annals of Epidemiology, vol. 17, no. 3, pp. 227–236, 2007. [29] R. Deo, C. L. Wassel Fyr, L. F. Fried et al., “Kidney dysfunction and fatal cardiovascular disease-an association independent of atherosclerotic events: results from the Health, Aging, and Body Composition (Health ABC) study,” American Heart Journal, vol. 155, no. 1, pp. 62–68, 2008. [30] Y. Iwashima, T. Horio, K. Kamide et al., “Additive interaction of metabolic syndrome and chronic kidney disease on cardiac hypertrophy, and risk of cardiovascular disease in hyperten- sion,” American Journal of Hypertension, vol. 23, no. 3, pp. 290– 298, 2010. [31] D. Martins, C. Ani, D. Pan, O. Ogunyemi, and K. Norris, “Renal dysfunction, metabolic syndrome and cardiovascular disease mortality,” Journal of Nutrition and Metabolism, vol. 2010, Article ID 167162, 8 pages, 2010. [32] L. Risch, R. Herklotz, A. Blumberg, and A. R. Huber, “Eﬀects of glucocorticoid immunosuppression on serum cystatin C Cardiology Research and Practice concentrations in renal transplant patients,” Clinical Chem- istry, vol. 47, no. 11, pp. 2055–2059, 2001. [33] P. Wiesli, B. Schwegler, G. A. Spinas, and C. Schmid, “Serum cystatin C is sensitive to small changes in thyroid function,” Clinica Chimica Acta, vol. 338, no. 1-2, pp. 87–90, 2003.